Aegis Therapeutics LLC, of San Diego, said its Intravail technology was formulated successfully with phenylephrine in compressed tablets, improving oral bioavailability by more than 50 percent. It marked the first application of Intravail, a drug delivery platform designed for non-invasive delivery of protein, peptide and nonpeptide drugs currently administered only via injection, in a solid dosage form.